Does the media favor MMSI or CNMD?

In the previous week, Merit Medical Systems had 1 more articles in the media than CONMED. MarketBeat recorded 3 mentions for Merit Medical Systems and 2 mentions for CONMED. Merit Medical Systems' average media sentiment score of 1.36 beat CONMED's score of 0.00 indicating that Merit Medical Systems is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Merit Medical Systems 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CONMED 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CNMD or IRTC?

In the previous week, CONMED and CONMED both had 2 articles in the media. iRhythm Technologies' average media sentiment score of 0.92 beat CONMED's score of 0.00 indicating that iRhythm Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CONMED 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral iRhythm Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, WRBY or CNMD?

CONMED has higher revenue and earnings than Warby Parker. CONMED is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Warby Parker $871.91M 3.69 $1.64M $0.02 1,501.05 CONMED $1.37B 0.76 $47.06M $1.77 19.50

Does the media favor WRBY or CNMD?

In the previous week, Warby Parker had 4 more articles in the media than CONMED. MarketBeat recorded 6 mentions for Warby Parker and 2 mentions for CONMED. Warby Parker's average media sentiment score of 1.16 beat CONMED's score of 0.00 indicating that Warby Parker is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Warby Parker 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive CONMED 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CNMD or TMDX?

In the previous week, TransMedics Group had 1 more articles in the media than CONMED. MarketBeat recorded 3 mentions for TransMedics Group and 2 mentions for CONMED. TransMedics Group's average media sentiment score of 0.63 beat CONMED's score of 0.00 indicating that TransMedics Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CONMED 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TransMedics Group 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CNMD or ESTA?

In the previous week, Establishment Labs had 2 more articles in the media than CONMED. MarketBeat recorded 4 mentions for Establishment Labs and 2 mentions for CONMED. Establishment Labs' average media sentiment score of 0.66 beat CONMED's score of 0.00 indicating that Establishment Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CONMED 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Establishment Labs 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

CONMED (CNMD) Competitors

$34.51 -1.44 (-4.01%)

Closing price 03:59 PM Eastern

Extended Trading

$33.86 -0.64 (-1.86%)

As of 05:29 PM Eastern

Compare

CNMD vs. MMSI, IRTC, WRBY, TMDX, and ESTA

Should you buy CONMED stock or one of its competitors? MarketBeat compares CONMED with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CONMED include Merit Medical Systems (MMSI), iRhythm Technologies (IRTC), Warby Parker (WRBY), TransMedics Group (TMDX), and Establishment Labs (ESTA).

How does CONMED compare to Merit Medical Systems?

Merit Medical Systems (NASDAQ:MMSI) and CONMED (NYSE:CNMD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Merit Medical Systems currently has a consensus price target of $92.80, suggesting a potential upside of 32.40%. CONMED has a consensus price target of $39.50, suggesting a potential upside of 14.47%. Given Merit Medical Systems' stronger consensus rating and higher probable upside, research analysts clearly believe Merit Medical Systems is more favorable than CONMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Merit Medical Systems	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
CONMED	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

99.7% of Merit Medical Systems shares are owned by institutional investors. 0.7% of Merit Medical Systems shares are owned by company insiders. Comparatively, 0.3% of CONMED shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Merit Medical Systems has a net margin of 9.03% compared to CONMED's net margin of 4.00%. CONMED's return on equity of 13.84% beat Merit Medical Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Merit Medical Systems	9.03%	13.54%	7.94%
CONMED	4.00%	13.84%	6.05%

In the previous week, Merit Medical Systems had 1 more articles in the media than CONMED. MarketBeat recorded 3 mentions for Merit Medical Systems and 2 mentions for CONMED. Merit Medical Systems' average media sentiment score of 1.36 beat CONMED's score of 0.00 indicating that Merit Medical Systems is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Merit Medical Systems	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CONMED	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Merit Medical Systems has higher revenue and earnings than CONMED. CONMED is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Merit Medical Systems	$1.52B	2.76	$128.49M	$2.31	30.34
CONMED	$1.37B	0.76	$47.06M	$1.77	19.50

Merit Medical Systems has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, CONMED has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market.

Summary

Merit Medical Systems beats CONMED on 14 of the 16 factors compared between the two stocks.

How does CONMED compare to iRhythm Technologies?

CONMED (NYSE:CNMD) and iRhythm Technologies (NASDAQ:IRTC) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

CONMED presently has a consensus target price of $39.50, indicating a potential upside of 14.47%. iRhythm Technologies has a consensus target price of $187.38, indicating a potential upside of 58.24%. Given iRhythm Technologies' stronger consensus rating and higher probable upside, analysts clearly believe iRhythm Technologies is more favorable than CONMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CONMED	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94

CONMED has a net margin of 4.00% compared to iRhythm Technologies' net margin of -3.53%. CONMED's return on equity of 13.84% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CONMED	4.00%	13.84%	6.05%
iRhythm Technologies	-3.53%	-10.26%	-1.39%

In the previous week, CONMED and CONMED both had 2 articles in the media. iRhythm Technologies' average media sentiment score of 0.92 beat CONMED's score of 0.00 indicating that iRhythm Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CONMED	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
iRhythm Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CONMED has higher revenue and earnings than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CONMED	$1.37B	0.76	$47.06M	$1.77	19.50
iRhythm Technologies	$747.14M	5.21	-$44.55M	-$0.86	N/A

CONMED has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

Summary

iRhythm Technologies beats CONMED on 7 of the 13 factors compared between the two stocks.

How does CONMED compare to Warby Parker?

Warby Parker (NYSE:WRBY) and CONMED (NYSE:CNMD) are both medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

Warby Parker currently has a consensus target price of $29.82, indicating a potential downside of 0.68%. CONMED has a consensus target price of $39.50, indicating a potential upside of 14.47%. Given CONMED's higher probable upside, analysts plainly believe CONMED is more favorable than Warby Parker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Warby Parker	0 Sell rating(s)	5 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.67
CONMED	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

93.2% of Warby Parker shares are held by institutional investors. 16.8% of Warby Parker shares are held by insiders. Comparatively, 0.3% of CONMED shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Warby Parker has a beta of 1.96, indicating that its share price is 96% more volatile than the broader market. Comparatively, CONMED has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market.

In the previous week, Warby Parker had 4 more articles in the media than CONMED. MarketBeat recorded 6 mentions for Warby Parker and 2 mentions for CONMED. Warby Parker's average media sentiment score of 1.16 beat CONMED's score of 0.00 indicating that Warby Parker is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Warby Parker	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
CONMED	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CONMED has a net margin of 4.00% compared to Warby Parker's net margin of 0.15%. CONMED's return on equity of 13.84% beat Warby Parker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Warby Parker	0.15%	2.30%	1.18%
CONMED	4.00%	13.84%	6.05%

CONMED has higher revenue and earnings than Warby Parker. CONMED is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Warby Parker	$871.91M	3.69	$1.64M	$0.02	1,501.05
CONMED	$1.37B	0.76	$47.06M	$1.77	19.50

Summary

Warby Parker beats CONMED on 9 of the 16 factors compared between the two stocks.

How does CONMED compare to TransMedics Group?

CONMED (NYSE:CNMD) and TransMedics Group (NASDAQ:TMDX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

In the previous week, TransMedics Group had 1 more articles in the media than CONMED. MarketBeat recorded 3 mentions for TransMedics Group and 2 mentions for CONMED. TransMedics Group's average media sentiment score of 0.63 beat CONMED's score of 0.00 indicating that TransMedics Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CONMED	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TransMedics Group	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.7% of TransMedics Group shares are owned by institutional investors. 0.3% of CONMED shares are owned by insiders. Comparatively, 6.9% of TransMedics Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

TransMedics Group has a net margin of 27.04% compared to CONMED's net margin of 4.00%. TransMedics Group's return on equity of 22.38% beat CONMED's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CONMED	4.00%	13.84%	6.05%
TransMedics Group	27.04%	22.38%	8.46%

TransMedics Group has lower revenue, but higher earnings than CONMED. TransMedics Group is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CONMED	$1.37B	0.76	$47.06M	$1.77	19.50
TransMedics Group	$605.49M	3.84	$190.29M	$4.40	15.29

CONMED currently has a consensus target price of $39.50, indicating a potential upside of 14.47%. TransMedics Group has a consensus target price of $134.50, indicating a potential upside of 99.88%. Given TransMedics Group's stronger consensus rating and higher probable upside, analysts clearly believe TransMedics Group is more favorable than CONMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CONMED	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
TransMedics Group	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46

CONMED has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market.

Summary

TransMedics Group beats CONMED on 15 of the 16 factors compared between the two stocks.

How does CONMED compare to Establishment Labs?

CONMED (NYSE:CNMD) and Establishment Labs (NASDAQ:ESTA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

CONMED has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market. Comparatively, Establishment Labs has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

72.9% of Establishment Labs shares are held by institutional investors. 0.3% of CONMED shares are held by company insiders. Comparatively, 10.0% of Establishment Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Establishment Labs had 2 more articles in the media than CONMED. MarketBeat recorded 4 mentions for Establishment Labs and 2 mentions for CONMED. Establishment Labs' average media sentiment score of 0.66 beat CONMED's score of 0.00 indicating that Establishment Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CONMED	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Establishment Labs	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CONMED has a net margin of 4.00% compared to Establishment Labs' net margin of -19.05%. CONMED's return on equity of 13.84% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CONMED	4.00%	13.84%	6.05%
Establishment Labs	-19.05%	-218.77%	-12.31%

CONMED currently has a consensus price target of $39.50, suggesting a potential upside of 14.47%. Establishment Labs has a consensus price target of $87.14, suggesting a potential downside of 0.32%. Given CONMED's higher possible upside, research analysts plainly believe CONMED is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CONMED	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

CONMED has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CONMED	$1.37B	0.76	$47.06M	$1.77	19.50
Establishment Labs	$211.08M	12.19	-$51.06M	-$1.49	N/A

Summary

Establishment Labs beats CONMED on 8 of the 15 factors compared between the two stocks.

Get CONMED News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNMD vs. The Competition

Export

Metric	CONMED	MED/DENTAL Industry	Medical Sector	NYSE Exchange
Market Cap	$1.08B	$16.29B	$6.84B	$23.40B
Dividend Yield	N/A	1.28%	2.67%	4.08%
P/E Ratio	7.90	18.82	25.83	31.73
Price / Sales	0.76	2.38	511.51	82.26
Price / Cash	4.99	14.20	29.09	18.60
Price / Book	1.03	3.33	10.98	4.78
Net Income	$47.06M	$534.24M	$3.57B	$1.07B
7 Day Performance	6.17%	3.73%	3.06%	1.42%
1 Month Performance	-3.50%	2.94%	0.72%	0.76%
1 Year Performance	-33.65%	1.44%	36.82%	25.45%

CONMED Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNMD CONMED	3.085 of 5 stars	$34.51 -4.0%	$39.50 +14.5%	-31.1%	$1.08B	$1.37B	7.90	3,900	Analyst Forecast Gap Down
MMSI Merit Medical Systems	4.2226 of 5 stars	$66.50 -1.1%	$92.80 +39.5%	-23.3%	$4.01B	$1.54B	28.79	7,500	Positive News
IRTC iRhythm Technologies	4.5036 of 5 stars	$104.69 +0.0%	$187.38 +79.0%	-23.2%	$3.44B	$787.85M	N/A	2,400
WRBY Warby Parker	2.5687 of 5 stars	$26.95 +3.8%	$29.50 +9.4%	+33.0%	$2.78B	$871.91M	1,348.32	4,036	Positive News Analyst Forecast Gap Up
TMDX TransMedics Group	4.2301 of 5 stars	$75.51 -4.2%	$134.50 +78.1%	-47.9%	$2.72B	$605.49M	17.16	210

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CNMD) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CONMED (CNMD) Competitors

CNMD vs. MMSI, IRTC, WRBY, TMDX, and ESTA

How does CONMED compare to Merit Medical Systems?

Summary

How does CONMED compare to iRhythm Technologies?

Summary

How does CONMED compare to Warby Parker?

Summary

How does CONMED compare to TransMedics Group?

Summary

How does CONMED compare to Establishment Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNMD vs. The Competition

CONMED Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CONMED (CNMD) Competitors

CNMD vs. MMSI, IRTC, WRBY, TMDX, and ESTA

How does CONMED compare to Merit Medical Systems?

Do analysts recommend MMSI or CNMD?

Do institutionals & insiders have more ownership in MMSI or CNMD?

Is MMSI or CNMD more profitable?

Does the media favor MMSI or CNMD?

Which has preferable earnings and valuation, MMSI or CNMD?

Which has more volatility & risk, MMSI or CNMD?

Summary

How does CONMED compare to iRhythm Technologies?

Do analysts recommend CNMD or IRTC?

Is CNMD or IRTC more profitable?

Does the media refer more to CNMD or IRTC?

Which has better earnings and valuation, CNMD or IRTC?

Which has more risk and volatility, CNMD or IRTC?

Summary

How does CONMED compare to Warby Parker?

Do analysts recommend WRBY or CNMD?

Do insiders & institutionals have more ownership in WRBY or CNMD?

Which has more risk and volatility, WRBY or CNMD?

Does the media favor WRBY or CNMD?

Is WRBY or CNMD more profitable?

Which has better valuation & earnings, WRBY or CNMD?

Summary

How does CONMED compare to TransMedics Group?

Does the media refer more to CNMD or TMDX?

Do insiders and institutionals believe in CNMD or TMDX?

Is CNMD or TMDX more profitable?

Which has stronger earnings and valuation, CNMD or TMDX?

Do analysts recommend CNMD or TMDX?

Which has more risk & volatility, CNMD or TMDX?

Summary

How does CONMED compare to Establishment Labs?

Which has more volatility and risk, CNMD or ESTA?

Do insiders & institutionals believe in CNMD or ESTA?

Does the media refer more to CNMD or ESTA?

Is CNMD or ESTA more profitable?

Do analysts rate CNMD or ESTA?

Which has better earnings & valuation, CNMD or ESTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNMD vs. The Competition

CONMED Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools